Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging

Published on Aug 1, 2017in European Journal of Nuclear Medicine and Molecular Imaging7.081
· DOI :10.1007/S00259-017-3780-7
Uwe Haberkorn85
Estimated H-index: 85
(University Hospital Heidelberg)
Sources
Abstract
Background The rapidly expanding clinical adaptation of prostate-specific membrane antigen (PSMA)-targeted PET imaging in the evaluation of patients with prostate cancer has placed an increasing onus on understanding both the potential pearls of interpretation as well as limitations of this new technique. As with any new molecular imaging modality, accurate characterization of abnormalities on PSMA-targeted PET imaging can be accomplished only if one is aware of the normal distribution pattern, physiological variants of radiotracer uptake, and potential sources of false-positive and false-negative imaging findings. In recent years, a growing number of reports have come to light describing incidental non-prostatic benign or malignant pathologies with high uptake on PSMA-targeted PET imaging. In this review, we have summarized the published literature regarding the potential pearls and technical and interpretive pitfalls of this imaging modality. Knowledge of these limitations can increase the confidence of interpreting physicians and thus improve patient care.
📖 Papers frequently viewed together
740 Citations
68 Citations
241 Citations
References177
Newest
#10Matthias Eiber (TUM: Technische Universität München)
: The study aims to investigate the presence of physiologic prostate-specific membrane antigen (68Ga-PSMA)-ligand uptake on PET in cervical, celiac, and sacral ganglia of the sympathetic trunk as a pitfall for lymph node metastases in prostate cancer imaging. Methods: Four hundred seven patients who underwent Glu-NH-CO-NH-Lys radiolabeled with 68Ga-gallium N,N-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N-diacetic acid (68Ga-PSMA-HBED-CC) PET (combined with a diagnostic CT) were retro...
68 CitationsSource
#1Shankar VamadevanH-Index: 5
#2Ken LeH-Index: 6
Last. Robert MansbergH-Index: 15
view all 5 authors...
: A 66-year-old man with recently diagnosed prostate cancer (Gleason score 9) was referred for Ga-prostate-specific membrane antigen (PSMA) PET/CT with prostate-specific antigen level of 7.5 μg/L. PET/CT demonstrated increased PSMA uptake (SUVmax 4.7) in a soft tissue density in the left adductor compartment. MRI and cytopathology of the biopsied soft tissue density was compatible with a peripheral nerve sheath tumor. This case illustrates that PSMA uptake can occur in a peripheral nerve sheath ...
14 CitationsSource
#1Shambo Guha Roy (AIIMS: All India Institute of Medical Sciences)H-Index: 6
Last. Chandrasekhar BalH-Index: 35
view all 6 authors...
In vitro and in vivo studies have demonstrated prostate-specific membrane antigen (PSMA) expression in various malignant and benign tumors. Based on the recent immunohistochemical study showing PSMA expression in adenocarcinoma of urinary bladder, we hypothesized that PSMA expression in adenocarcinoma of urinary bladder can be demonstrated in vivo using Ga-PSMA 11 PET/CT. We present a man with exstrophy bladder, presenting with adenocarcinoma urinary bladder referred for staging PET/CT. Both F-F...
15 CitationsSource
#1Isabel Rauscher (TUM: Technische Universität München)H-Index: 20
#2Tobias MaurerH-Index: 53
Last. Matthias EiberH-Index: 55
view all 5 authors...
: Ga prostate-specific membrane antigen (PSMA) HBED-CC PET/CT in a 65-year-old man with first diagnosis of prostate cancer (PC) and a history of multiple myeloma showing multifocal PSMA ligand uptake in the skeleton with corresponding osteolytic lesions in CT. Although osteolytic bone metastases are very rare in PC, PSMA expression in PET raised the suspicion of PC bone metastases. Bone marrow biopsy excluded PC metastases with immunohistochemistry showing endothelial expression of PSMA in small...
20 CitationsSource
#1Lise Hangaard (Aarhus University Hospital)H-Index: 1
#2Mads JochumsenH-Index: 15
Last. Kirsten BoucheloucheH-Index: 17
view all 4 authors...
: Ga-PSMA PET/CT is currently used for detection of prostate cancer including metastases, even at low prostate-specific antigen values. A grown number of reports have shown increased uptake of PSMA in neovessels of nonprostatic malignancies including lung cancer, and recently a case report has demonstrated increased PSMA uptake in colorectal adenocarcinoma. In this case report, we demonstrate increased Ga-PMSA uptake on PET/CT in metastases from previously treated colon adenocarcinoma, and it il...
22 CitationsSource
#1Felix DietleinH-Index: 15
#2Carsten KobeH-Index: 30
Last. Markus DietleinH-Index: 46
view all 12 authors...
: Several studies outlined the sensitivity of 68Ga-labeled PET tracers against the prostate-specific membrane antigen (PSMA) for localization of relapsed prostate cancer in patients with renewed increase in the prostate-specific antigen (PSA), commonly referred to as biochemical recurrence. Labeling of PSMA tracers with 18F offers numerous advantages, including improved image resolution, longer half-life, and increased production yields. The aim of this study was to assess the PSA-stratified per...
90 CitationsSource
#1Arun SasikumarH-Index: 11
#2Ajith JoyH-Index: 11
Last. Geetha NarayananH-Index: 1
view all 5 authors...
AbstractFibrous dysplasia (FD) is a benign bone lesion with a rare but potential for malignant transformation. Neither 99mTc-MDP nor 18F-FDG PET/CT can differentiate between FD and areas of malignant transformation in FD. We described a case of osteosarcoma developing in FD with selective uptake of
24 CitationsSource
#2Turkay HekimsoyH-Index: 2
Last. Hakan DemirH-Index: 10
view all 5 authors...
: Ga prostate-specific membrane antigen (PSMA) PET/CT is a promising tool for imaging of prostate cancer. Ga-PSMA PET/CT uptake of prostate cancer and its metastases are reflective of significant overexpression of PSMA. However, PSMA expression of benign neoplasms and nonprostate epithelial malignancies is not very well defined. We report a moderate Ga-PSMA uptake of an acrochordon (skin tag), which was incidentally found in a patient referred for staging prostate cancer. Acrochordon is a freque...
7 CitationsSource
#5Uwe Haberkorn (University Hospital Heidelberg)H-Index: 85
37 CitationsSource
#1Helle D ZachoH-Index: 14
#2Julie B. NielsenH-Index: 7
Last. Lars Jelstrup PetersenH-Index: 28
view all 5 authors...
Abstract68Ga-PSMA PET/CT is becoming the most promising imaging modality for detecting recurrent prostate cancer. The modality has the advantage of being able to detect recurrent disease, even at very low prostate-specific antigen levels. However, several studies report 68Ga-PSMA uptake in tissue un
14 CitationsSource
Cited By149
Newest
Over the last decade, upconversion nanoparticles (UCNP) have been widely investigated in nanomedicine due to their high potential as imaging agents in the near-infrared (NIR) optical window of biological tissues. Here, we successfully develop active targeted UCNP as potential probes for dual NIR-NIR fluorescence and radioactive-guided surgery of prostate-specific membrane antigen (PSMA)(+) prostate cancers. We designed a one-pot thermolysis synthesis method to obtain oleic acid-coated spherical ...
Source
#1Rita Viglialoro (UniPi: University of Pisa)
#2Enrica Esposito (UniPi: University of Pisa)
Last. Paola Anna Erba (UniPi: University of Pisa)H-Index: 31
view all 0 authors...
Brain metastases from prostate cancer typically occur in the more advanced stages of the disease. Clinically, the early diagnosis of visceral disease is crucial, impacting on patient's management and prognosis. Although magnetic resonance imaging (MRI) is the modality of choice for the detection of brain metastases, it is not routinely performed in the surveillance of prostate cancer patients unless neurological manifestations appear. Prostate-specific membrane antigen (PSMA) is a glycoprotein, ...
Source
#1Markus Kroenke (TUM: Technische Universität München)H-Index: 5
#2Lilit Mirzoyan (TUM: Technische Universität München)H-Index: 1
Last. Isabel Rauscher (TUM: Technische Universität München)H-Index: 20
view all 10 authors...
Purpose: Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands are a new class of prostate cancer theranostic agents. 18F-rhPSMA-7, offers the advantages of 18F-labelling and low urinary excretion compared with 68Ga-PSMA-11. Here, we compare frequency of non-tumor related uptake and tumor positivity with 68Ga-PSMA-11 and 18F-rhPSMA-7 in patients with primary or recurrent prostate cancer. Methods: This retrospective matched-pair comparison matched 160 18F-rhPSMA-7 with 160 68Ga-PSMA-11 ...
5 CitationsSource
#1Luping QinH-Index: 2
#2Jie Lv (SYSU: Sun Yat-sen University)H-Index: 2
Last. Mu-hua Cheng (SYSU: Sun Yat-sen University)H-Index: 5
view all 7 authors...
Source
#1Konstantin SeitzerH-Index: 1
#2Robert SeifertH-Index: 10
Last. Kambiz RahbarH-Index: 22
view all 7 authors...
Patients suffering from metastatic castration-resistant prostate cancer (mCRPC) have a poor prognosis. As a further treatment option 177Lutetium (Lu) prostate-specific membrane antigen (PSMA) radioligand therapy gained a significant interest of many investigators. Several publications showed great response and prolonged survival with limited adverse events. However, to this point, it still remains unclear which patients benefit the most from 177Lu-PSMA therapy, and how to improve the treatment r...
Source
#1Riccardo Mei (UNIBO: University of Bologna)H-Index: 2
#2Andrea FarolfiH-Index: 8
Last. Stefano Fanti (UNIBO: University of Bologna)H-Index: 83
view all 6 authors...
2-deoxy-2-[18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) gained an impressive role in the diagnostic management of many oncological diseases, even though its use in imaging prostate cancer (PC) is limited to selected cases, mostly advanced stage of PC and selection for prostate specific antigen membrane (PSMA) radioligand therapy (RLT). In the past years, several PET tracers have been developed for both staging and restaging PC. The three most employed PET molecules in daily pr...
Source
#1Nicolò Capobianco (TUM: Technische Universität München)H-Index: 2
#2Ludovic Sibille (Siemens)H-Index: 2
Last. Matthias Eiber (TUM: Technische Universität München)H-Index: 55
view all 13 authors...
In PSMA-ligand PET/CT imaging, standardized evaluation frameworks and image-derived parameters are increasingly used to support prostate cancer staging. Clinical applicability remains challenging wherever manual measurements of numerous suspected lesions are required. Deep learning methods are promising for automated image analysis, typically requiring extensive expert-annotated image datasets to reach sufficient accuracy. We developed a deep learning method to support image-based staging, inves...
Source
#1Robert SeifertH-Index: 10
#2Ian AlbertsH-Index: 10
Last. Kambiz RahbarH-Index: 22
view all 4 authors...
Prostate-specific membrane antigen (PSMA) has been the subject of numerous studies within the last 3 decades. PSMA-targeted imaging and therapy have significantly changed the management of patients with prostate cancer in various disease stages, especially in advanced metastasized castration-resistant prostate cancer. Lutetium-177-conjugated PSMA-617 or PSMA-I&T (Lu-PSMA) has shown promising results in multicenter retrospective and monocenter prospective trials. The aim of this review is to prov...
Source
#1Ian Alberts (University of Bern)H-Index: 10
#2Robert Seifert (DKFZ: German Cancer Research Center)
Last. Ali Afshar-Oromieh (University of Bern)H-Index: 37
view all 4 authors...
Prostate-specific membrane antigen-PET/computed tomography (PSMA-PET/CT) is the investigation of choice for imaging prostate cancer. Demonstrating high diagnostic accuracy, PSMA-PET/CT detects disease at very early stages of recurrence, where the chances of a definitive cure may be at their greatest. A number of PSMA-radioligands are in established clinical routine, and there are currently only limited data and no single tracer can clearly be advocated over the others at present. Further clinica...
Source
#1Ingrid Jenny Guldvik (Oslo University Hospital)H-Index: 9
Last. Wolfgang Lilleby (Oslo University Hospital)H-Index: 18
view all 6 authors...
De novo metastatic or recurrence of prostate cancer (PC) remains life-threatening. Circulating tumor cells (CTCs) are noninvasive biomarkers and provide unique information that could enable tailored treatment. This study evaluated the impact of CTCs in PC patients eligible for peptide vaccine therapy. Twenty-seven patients were tested for CTCs with the CellCollector® device (Detector CANCER01(DC01)) during short-term androgen deprivation therapy (ADT) before cancer vaccine treatment (cohort 1) o...
Source